Tempest Therapeutics gets Nasdaq bid-price notice; TPST has until May 3, 2027 to top $1.00

Tempest Therapeutics, Inc.

Nasdaq Listing Qualifications Staff letter dated Nov. 4, 2026: TPST common stock closed below $1.00 for the last 30 consecutive business days, violating Rule 5550(a)(2).
Company has 180 calendar days, until May 3, 2027, to regain compliance; requires a closing bid of at least $1.00 for a minimum of 10 consecutive business days.
Notice has no immediate effect on the Nasdaq listing of TPST shares or on business operations, per the filing.
If not cured by May 3, 2027, Tempest may qualify for a second 180-day period if it meets market-value and other Capital Market standards and signals a reverse split if needed.
Company said it will actively monitor its closing bid price and evaluate options to resolve the deficiency; CEO Matthew Angel signed the filing Nov. 5, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.